<?xml version='1.0' encoding='utf-8'?>
<document id="17900172"><sentence text="Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites."><entity charOffset="45-54" id="DDI-PubMed.17900172.s1.e0" text="flutamide" /><entity charOffset="83-96" id="DDI-PubMed.17900172.s1.e1" text="acetaminophen" /><pair ddi="false" e1="DDI-PubMed.17900172.s1.e0" e2="DDI-PubMed.17900172.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s1.e0" e2="DDI-PubMed.17900172.s1.e1" /></sentence><sentence text="Treatment with flutamide has been associated with clinical hepatotoxicty"><entity charOffset="15-24" id="DDI-PubMed.17900172.s2.e0" text="flutamide" /></sentence><sentence text=" The toxicity, metabolism,and transport of flutamide were investigated using cultured human hepatocytes"><entity charOffset="43-52" id="DDI-PubMed.17900172.s3.e0" text="flutamide" /></sentence><sentence text=" Flutamide and its major metabolite, 2-hydroxyflutamide, caused an inhibition of taurocholate efflux in human hepatocytes with an IC50=75 microM and 110 microM, respectively"><entity charOffset="1-10" id="DDI-PubMed.17900172.s4.e0" text="Flutamide" /><entity charOffset="37-55" id="DDI-PubMed.17900172.s4.e1" text="2-hydroxyflutamide" /><entity charOffset="81-93" id="DDI-PubMed.17900172.s4.e2" text="taurocholate" /><pair ddi="false" e1="DDI-PubMed.17900172.s4.e0" e2="DDI-PubMed.17900172.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s4.e0" e2="DDI-PubMed.17900172.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s4.e0" e2="DDI-PubMed.17900172.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s4.e1" e2="DDI-PubMed.17900172.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s4.e1" e2="DDI-PubMed.17900172.s4.e2" /></sentence><sentence text=" Treatment of hepatocytes with flutamide or 2-hydroxyflutamide for 24 h resulted in time- and concentration-dependent toxicity as assessed by inhibition of protein synthesis"><entity charOffset="31-40" id="DDI-PubMed.17900172.s5.e0" text="flutamide" /><entity charOffset="44-62" id="DDI-PubMed.17900172.s5.e1" text="2-hydroxyflutamide" /><pair ddi="false" e1="DDI-PubMed.17900172.s5.e0" e2="DDI-PubMed.17900172.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s5.e0" e2="DDI-PubMed.17900172.s5.e1" /></sentence><sentence text=" Toxicity was greater after 1 h than after 24 h of treatment" /><sentence text=" Recovery in inhibition of protein synthesis by 24 h was attributed to the decreased presence of flutamide due to its metabolism"><entity charOffset="97-106" id="DDI-PubMed.17900172.s7.e0" text="flutamide" /></sentence><sentence text=" Flutamide was metabolized by hepatocytes to several metabolites, and formation of reactive intermediates of flutamide, as evidenced by the presence of glutathione-related adducts, was observed"><entity charOffset="1-10" id="DDI-PubMed.17900172.s8.e0" text="Flutamide" /><entity charOffset="109-118" id="DDI-PubMed.17900172.s8.e1" text="flutamide" /><entity charOffset="152-163" id="DDI-PubMed.17900172.s8.e2" text="glutathione" /><pair ddi="false" e1="DDI-PubMed.17900172.s8.e0" e2="DDI-PubMed.17900172.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s8.e0" e2="DDI-PubMed.17900172.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s8.e0" e2="DDI-PubMed.17900172.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s8.e1" e2="DDI-PubMed.17900172.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s8.e1" e2="DDI-PubMed.17900172.s8.e2" /></sentence><sentence text=" Inhibition of flutamide metabolism by 1-aminobenzotriazole (ABT) resulted in enhancement of flutamide toxicity, which was associated with sustained levels of nonmetabolized drug"><entity charOffset="15-24" id="DDI-PubMed.17900172.s9.e0" text="flutamide" /><entity charOffset="39-59" id="DDI-PubMed.17900172.s9.e1" text="1-aminobenzotriazole" /><entity charOffset="61-64" id="DDI-PubMed.17900172.s9.e2" text="ABT" /><entity charOffset="93-102" id="DDI-PubMed.17900172.s9.e3" text="flutamide" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e0" e2="DDI-PubMed.17900172.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e0" e2="DDI-PubMed.17900172.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e0" e2="DDI-PubMed.17900172.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e0" e2="DDI-PubMed.17900172.s9.e3" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e1" e2="DDI-PubMed.17900172.s9.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e1" e2="DDI-PubMed.17900172.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e1" e2="DDI-PubMed.17900172.s9.e3" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e2" e2="DDI-PubMed.17900172.s9.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s9.e2" e2="DDI-PubMed.17900172.s9.e3" /></sentence><sentence text=" ABT also prevented the formation of reactive intermediates of flutamide"><entity charOffset="63-72" id="DDI-PubMed.17900172.s10.e0" text="flutamide" /><entity charOffset="1-9" id="DDI-PubMed.17900172.s10.e1" text="ABT" /><pair ddi="false" e1="DDI-PubMed.17900172.s10.e1" e2="DDI-PubMed.17900172.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s10.e1" e2="DDI-PubMed.17900172.s10.e0" /></sentence><sentence text=" There was an additive toxicity when cells were treated with a combination of flutamide and 2-hydroxyflutamide"><entity charOffset="78-87" id="DDI-PubMed.17900172.s11.e0" text="flutamide" /><entity charOffset="92-110" id="DDI-PubMed.17900172.s11.e1" text="2-hydroxyflutamide" /><pair ddi="false" e1="DDI-PubMed.17900172.s11.e0" e2="DDI-PubMed.17900172.s11.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s11.e0" e2="DDI-PubMed.17900172.s11.e1" /></sentence><sentence text=" Simultaneous treatment with flutamide and acetaminophen (APAP) resulted in additive to synergistic toxic effects"><entity charOffset="29-38" id="DDI-PubMed.17900172.s12.e0" text="flutamide" /><entity charOffset="43-56" id="DDI-PubMed.17900172.s12.e1" text="acetaminophen" /><entity charOffset="58-62" id="DDI-PubMed.17900172.s12.e2" text="APAP" /><pair ddi="false" e1="DDI-PubMed.17900172.s12.e0" e2="DDI-PubMed.17900172.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s12.e0" e2="DDI-PubMed.17900172.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s12.e0" e2="DDI-PubMed.17900172.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s12.e1" e2="DDI-PubMed.17900172.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s12.e1" e2="DDI-PubMed.17900172.s12.e2" /></sentence><sentence text=" Flutamide and APAP were found to have significant effects on each other's metabolism"><entity charOffset="1-10" id="DDI-PubMed.17900172.s13.e0" text="Flutamide" /><entity charOffset="15-23" id="DDI-PubMed.17900172.s13.e1" text="APAP" /><pair ddi="false" e1="DDI-PubMed.17900172.s13.e0" e2="DDI-PubMed.17900172.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s13.e0" e2="DDI-PubMed.17900172.s13.e1" /></sentence><sentence text=" Flutamide inhibited glucuronidation and sulfation of APAP, resulting in greater amounts of APAP available for bioactivation"><entity charOffset="1-10" id="DDI-PubMed.17900172.s14.e0" text="Flutamide" /><entity charOffset="54-62" id="DDI-PubMed.17900172.s14.e1" text="APAP" /><entity charOffset="92-100" id="DDI-PubMed.17900172.s14.e2" text="APAP" /><pair ddi="false" e1="DDI-PubMed.17900172.s14.e0" e2="DDI-PubMed.17900172.s14.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s14.e0" e2="DDI-PubMed.17900172.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s14.e0" e2="DDI-PubMed.17900172.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s14.e1" e2="DDI-PubMed.17900172.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s14.e1" e2="DDI-PubMed.17900172.s14.e2" /></sentence><sentence text=" APAP inhibited the hydroxylation of flutamide, and subsequent sulfation and acetylation of 4-nitro-3-(trifluoromethyl) aniline, a metabolite of flutamide"><entity charOffset="37-46" id="DDI-PubMed.17900172.s15.e0" text="flutamide" /><entity charOffset="92-127" id="DDI-PubMed.17900172.s15.e1" text="4-nitro-3-(trifluoromethyl) aniline" /><entity charOffset="145-154" id="DDI-PubMed.17900172.s15.e2" text="flutamide" /><entity charOffset="1-9" id="DDI-PubMed.17900172.s15.e3" text="APAP" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e3" e2="DDI-PubMed.17900172.s15.e3" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e3" e2="DDI-PubMed.17900172.s15.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e3" e2="DDI-PubMed.17900172.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e3" e2="DDI-PubMed.17900172.s15.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e0" e2="DDI-PubMed.17900172.s15.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e0" e2="DDI-PubMed.17900172.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e0" e2="DDI-PubMed.17900172.s15.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e1" e2="DDI-PubMed.17900172.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s15.e1" e2="DDI-PubMed.17900172.s15.e2" /></sentence><sentence text=" In summary, we suggest that inhibition of bile acid efflux by flutamide and its 2-hydroxy metabolite may play a role in flutamide-induced liver injury"><entity charOffset="63-72" id="DDI-PubMed.17900172.s16.e0" text="flutamide" /><entity charOffset="121-130" id="DDI-PubMed.17900172.s16.e1" text="flutamide" /><pair ddi="false" e1="DDI-PubMed.17900172.s16.e0" e2="DDI-PubMed.17900172.s16.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s16.e0" e2="DDI-PubMed.17900172.s16.e1" /></sentence><sentence text=" Both flutamide and 2-hydroxyflutamide are responsible for cytotoxicity if not metabolized"><entity charOffset="6-15" id="DDI-PubMed.17900172.s17.e0" text="flutamide" /><entity charOffset="20-38" id="DDI-PubMed.17900172.s17.e1" text="2-hydroxyflutamide" /><pair ddi="false" e1="DDI-PubMed.17900172.s17.e0" e2="DDI-PubMed.17900172.s17.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s17.e0" e2="DDI-PubMed.17900172.s17.e1" /></sentence><sentence text=" The data also suggest a possible drug-drug interaction between flutamide and APAP, resulting in inhibition of flutamide metabolism and increased APAP bioactivation and toxicity"><entity charOffset="64-73" id="DDI-PubMed.17900172.s18.e0" text="flutamide" /><entity charOffset="111-120" id="DDI-PubMed.17900172.s18.e1" text="flutamide" /><entity charOffset="78-86" id="DDI-PubMed.17900172.s18.e2" text="APAP" /><entity charOffset="146-154" id="DDI-PubMed.17900172.s18.e3" text="APAP" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e0" e2="DDI-PubMed.17900172.s18.e0" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e0" e2="DDI-PubMed.17900172.s18.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e0" e2="DDI-PubMed.17900172.s18.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e0" e2="DDI-PubMed.17900172.s18.e3" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e2" e2="DDI-PubMed.17900172.s18.e2" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e2" e2="DDI-PubMed.17900172.s18.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e2" e2="DDI-PubMed.17900172.s18.e3" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e1" e2="DDI-PubMed.17900172.s18.e1" /><pair ddi="false" e1="DDI-PubMed.17900172.s18.e1" e2="DDI-PubMed.17900172.s18.e3" /></sentence><sentence text="" /></document>